NOVUS

Year in Review: 2024 Timeline

Financial Performance Highlights:
- Revenue Growth: Achieved a 7.32% increase in gross revenue compared to the same period in 2023.
- Profit Margins: Gross profit margins improved from 40.4% (June 2023) to 45.4% (June 2024).
- EBITDA Increase: Reported a 20.4% rise in EBITDA, showcasing improved operational efficiency.
- Cash Position: Cash and cash equivalents grew by 4%, reflecting stronger financial health.
Shareholder Commitment:
- Maintained a stable capital structure with no common share dilution since June 15, 2021.
- No insider selling for nearly three years, highlighting investor confidence.

Direct-to-Consumer Platform Launch:
- Introduced a cannabis RX platform, designed to:
  - Provide direct sales to policyholders.
  - Offer pre-negotiated discounts to enhance affordability.
  - Build brand loyalty among cannabis consumers and healthcare providers.

Market Expansion Efforts:
- The platform targeted medical users, unregistered consumers from the illicit market, and recreational users.
- Created affordable wellness programs with customized insurance benefits.

Integration with Conventional Medicine:
- Plans to incorporate pharmaceutical medications alongside cannabis offerings.
- Aimed at creating a comprehensive healthcare solution for policyholders.

Focused on self-funded, independent growth without reliance on external capital.

This timeline highlights Novus’ resilience and adaptability in the evolving cannabis healthcare industry.

* Indicates Required Field

We are available Monday - Friday 9:00 am - 5:00 pm (EST) Email: info@getnovusnow.com